TauroLock™ is approved to be instilled into catheter-based devices for central venous access in order to maintain patency of the vascular access device. Additionally, by creating a hostile environment to bacterial and fungal growth, the risk of catheter-related bloodstream infections (CRBSI) is reduced.
Ingredients / Specification:
TauroLock™ contains anticoagulant and antimicrobial substances. Active ingredients in TauroLock™ are taurolidine and citrate (4%). The product is sterile filter processed and supplied as a clear, sterile, non-pyrogenic solution. TauroLock™ is to be used with a port or a catheter-based vascular access device. It is to be instilled into the device lumen between treatments (e.g. in hemodialysis, oncology, parenteral nutrition).
After treatment, the system is thoroughly flushed with saline (min. 10 mL). Then, TauroLock™ is instilled into the access system by exactly respecting the filling volume. TauroLock™ remains in the system until the next treatment. The solution must be aspirated before initiating the next treatment. If aspiration of TauroLock™ is not possible, slow ushing of TauroLock™ (not more than 1 mL per 3 seconds) prior to the next treatment is clinically tolerable. Flush the device with 10 mL of saline.
TauroLock™ is contraindicated for patients with a known allergy to citrate or taurolidine, and for patients currently taking medication with known adverse interaction to citrate or taurolidine.
TauroLock™ must be stored at 15 to 30 °C. It must be neither transported nor stored under freezing conditions. Ampoules are for single-dose only, vials are multi-dose and must be used within 48 hours after the first puncture.
Note: This information does not replace the instructions for use.
Description: TauroLock™ catheter lock solution 3 ml ampoule (single-dose)
Packaging: 10 x 3 ml
Description: TauroLock™ catheter lock solution 5 ml ampoule (single-dose)
Packaging: 10 x 5 ml
Description: TauroLock™ catheter lock solution 10 ml vial (multi-dose)
Packaging: 100 x 10 ml
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.